Last updated: 11/07/2018 14:48:26
A Multicentre, Double-Blind, Placebo Controlled, Parallel Group Comparative Study to Assess the Efficacy and Safety of Rosiglitazone with Concurrent Sulphonylurea Therapy when Administered to Subjects with Non-Insulin-Dependent Diabetes Mellitus (Type 2 Diabetes)
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Multicentre, Double-Blind, Placebo Controlled, Parallel Group Comparative Study to Assess the Efficacy and Safety of Rosiglitazone with Concurrent Sulphonylurea Therapy when Administered to Subjects with Non-Insulin-Dependent Diabetes Mellitus (Type 2 Diabetes)
Trial description: A Multicentre, Double-Blind, Placebo Controlled, Parallel Group Comparative Study to Assess the Efficacy and Safety of Rosiglitazone with Concurrent Sulphonylurea Therapy when Administered to Subjects with Non-Insulin-Dependent Diabetes Mellitus (Type 2 Diabetes)
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: Rosiglitazone Improves Glycemic Control in Chinase with Type 2 Diabetes Mellitus in Combination with Sulfonylurea, Xixing, Z; Changyu, P; Guangwei, L; Hongli, S; Hui, T; Wenying, Y; Xiaoyan, X; Jiang, J; Davies, C; Beck, S; Rut, A; Matfin, G; Philadelphia, PA; USA. 61st Annual Meeting of the American Diabetes Association. 6/22/2001
Xixing Z, Changyu P, Guangwei L, et al. Rosiglitazone has a favorable safety profile in Chinese type 2 diabetics with previous exposure to hepatitis B or C infection. Diabetes 2001; 50 (Suppl 2). Abs 1863-PO presented at ADA 2001.
Xixing Z, Changyu P, Guangwei L, et al. Rosiglitazone improves glycaemic control in Chinese patients with type 2 diabetes mellitus in combination with sulfonylurea. Diabetes 2001; 50 (Suppl 2). Abs 542-P presented at ADA 2001.
Zhu XX. Administration of rosiglitazone in combination with sulphonylurea provides safe and effective glycaemic control in Chinese patients with Type 2 diabetes mellitus. Diabetes Technol Ther 2003; 5:33-42.
Medical condition
Diabetes Mellitus, Type 2
Product
rosiglitazone
Collaborators
Not applicable
Study date(s)
April 1999 to February 2000
Type
Not applicable
Phase
2
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2000-02-02
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website